<DOC>
	<DOC>NCT02798679</DOC>
	<brief_summary>The purpose of this study is to determine whether pre-existing cardiac fibrosis is a predictor of cancer treatment-related cardiotoxicity.</brief_summary>
	<brief_title>Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity</brief_title>
	<detailed_description />
	<mesh_term>Cardiotoxicity</mesh_term>
	<criteria>Stage IIII breast cancer or lymphoma with a &gt;2 year life expectancy A treatment plan that includes anthracyclines and/or trastuzumab Age &gt;45 years Able to hold breath for 10 seconds Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Refusal or inability to provide informed consent Known heart failure or LVEF &lt;50% Heart rate over 100 bpm Renal dysfunction with GFR &lt;30 mL/min/1.73m2 Participants with pacemakers, defibrillators, functioning neurostimulator devices or other implanted electronic devices Symptomatic claustrophobia Plans to move within 24 months of enrollment</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>